Thursday, May 25, 2017 8:15:22 AM
Director at Hestia Investments
focus on early to mid stage public and private companies in biotechnology and renewable energy
From Thorn Medical website: http://www.thornmedical.com/corporate/advisory-panel
Marcus Malkmus
Marcus is co-founder and chairman of FimpactT AG, a Swiss-based technology consultancy.
Marcus has also worked as external consultant to Barchester Group, a financial advisory company focusing on special situations in biotechnology and IT. His main role was to look for potential client targets outside of the UK.
Marcus has degrees in Mathematics, Computer Science, Economics and Neuroscience from Universitaet Braunschweig, UCL and Oxford University. He is co-founder and board member of the Dyslexia Research Trust.
Hestia Connection (see previous post):
Kathrin Kortschank
Kathrin joined FimpactT AG in 2005 and was appointed a partner in 2009.
She is also co-founder of Hestia Investments, a company specialising in functional cosmetics and early-stage biotechnology investments.
Kathrin graduated in History and French Literature from Oxford University.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM